CLINICAL_TRIALS
trial_result
· 2022-10-07
Clinical Trial Update: Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation [Phase 2]
Summary
Phase 2 trial update on safety and efficacy of LNP023 in IgA nephropathy has been completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2022-10-07